National Coverage Determination (NCD) 210.3 - Screening for Colorectal Cancer (CRC) - Blood-Based Biomarker Tests

MLN Matters Number: MM12280
Related Change Request (CR) Number: 12280
Related CR Release Date: May 20, 2021
Effective Date: January 19, 2021
Related CR Transmittal Number: R10818CP and R10818NCD
Implementation Date: October 4, 2021

Provider Types Affected

This MLN Matters® Article is for physicians and providers who bill Medicare Administrative Contractors (MACs) for colorectal cancer (CRC) screening tests provided to Medicare patients.

Provider Types Affected

This Article tells you that CMS determined, effective January 19, 2021, the blood-based biomarker test is an appropriate CRC screening test based on specific criteria.

Background

Sections 1861(s)(2)(R) and 1861(pp) of the Social Security Act (the Act) and regulations at 42 Code of Federal Regulations (CFR) 410.37 authorize Medicare coverage for CRC screening tests under Medicare Part B. The statute and regulations authorize the HHS Secretary to add other tests and procedures (and modifications to such tests and procedures for CRC screening) as the Secretary determines in consultation with appropriate organizations.

Over the last several years, blood-based biomarker tests have emerged as another potential non-invasive option for the early detection of CRC. The blood-based biomarker measured in a person’s blood can be an indicator of a process, such as CRC disease risk or progression.

For services you perform on or after January 19, 2021, the blood-based biomarker test is an appropriate CRC screening test once every 3 years for Medicare patients when performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory, ordered by a treating physician, and when the following requirements are met.

The patient is:

- Aged 50-85 years
• Asymptomatic (no signs or symptoms of colorectal disease including but not limited to lower gastrointestinal pain, blood in stool, positive guaiac fecal occult blood test, or fecal immunochemical test); and,
• At average risk of developing CRC (no personal history of adenomatous polyps, or inflammatory bowel disease, including Crohn’s Disease and ulcerative colitis; no family history of CRCs or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis CRC).

The blood-based biomarker screening test must have:
• FDA market authorization with an indication for CRC screening; and,
• Proven test performance characteristics for a blood-based screening test with both sensitivity greater than or equal to 74% and specificity greater than or equal to 90% in the detection of CRC compared to the recognized standard (accepted as colonoscopy at this time), based on the pivotal studies included in the FDA labeling.

Effective for claims with dates of service on or after January 19, 2021, report at least 1 of the following diagnosis codes when submitting claims for the Blood-based Biomarker test HCPCS code G0327 (Colorectal cancer screening; blood-based biomarker):
• Z12.11 Encounter for screening for malignant neoplasm of colon
• Z12.12 Encounter for screening for malignant neoplasm of rectum

Effective for claims with dates of service on and after January 19, 2021, deductible and coinsurance don’t apply to the Blood-based biomarker test (HCPCS G0327)

Your MAC won’t search for prior claims containing HCPCS G0327 with dates of service on or after January 19, 2021. They will adjust such claims you bring to their attention.

More Information

We issued CR 12280 to your MAC as the official instruction via 2 transmittals. The first transmittal updates the Medicare Claims Processing Manual. The second transmittal updates the NCD Manual. The manual revisions are part of the transmittals.

For more information, contact your MAC.

Document History

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 26, 2021</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the
written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2020 American Medical Association. All rights reserved.

Copyright © 2013-2021, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.